Cellectis S.A. is a clinical-stage biotechnology company focused on gene editing and cell therapy. The company develops allogeneic CAR T-cell product candidates designed for immuno-oncology, along with gene-edited therapies for other serious diseases. Its platform centers on proprietary genome-editing technologies, including TALEN, which are used to engineer off-the-shelf therapeutic candidates intended for broad clinical use. Cellectis also works on hematopoietic stem and progenitor cell applications and other advanced therapeutic programs, positioning the company at the intersection of genetic engineering, immunotherapy, and precision medicine. Headquartered in Paris, France, Cellectis plays a specialized role in the biopharmaceutical market by advancing next-generation therapies built around engineered cells and targeted genetic modification.